$2.16
-0.14 (-6.09%)
Open$2.24
Previous Close$2.30
Day High$2.29
Day Low$2.14
52W High$3.40
52W Low$1.01
Volume—
Avg Volume476.6K
Market Cap239.81M
P/E Ratio—
EPS$-1.19
SectorBiotechnology
Analyst Ratings
Buy
14 analysts
Price Target
+886.1% upside
Current
$2.16
$2.16
Target
$21.30
$21.30
$14.71
$21.30 avg
$34.17
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 22.68M | 42.00M | 87.33M |
| Net Income | -154,069,643 | -256,735,194 | 8.20M |
| Profit Margin | -679.2% | -645.2% | 9.4% |
| EBITDA | -147,719,002 | -259,827,905 | 10.19M |
| Free Cash Flow | — | — | 6.96M |
| Rev Growth | -46.0% | -46.0% | +6.5% |
| Debt/Equity | 0.32 | 0.32 | 0.50 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |